Background. It has been postulated that short wait time before liver transplant (LT) for hepatocellular carcinoma (HCC) results in the inclusion of tumors with aggressive biology, but prolonged wait time could result in a shift to more aggressive tumor behavior. We therefore test the hypothesis that a wait time "sweet spot" exists with a lower risk for HCC recurrence compared with the other 2 extremes. Methods. This multicenter study included 911 patients from 3 LT centers with short, medium, and long wait times (median of 4, 7, and 13 months, respectively) who received Model for End Stage Liver Disease exception listing for HCC from 2002 to 2012. Results. Wait time, defined as time from initial HCC diagnosis to LT, was less than 6 months in 32.4%, 6 to 18 months in 53.7%, and greater than 18 months in 13.9%. Waitlist dropout was observed in 18.4% at a median of 11.3 months. Probability of HCC recurrence at 1 and 5 years were 6.4% and 15.5% with wait time of less than 6 or greater than 18 months (n = 343) versus 4.5% and 9.8% with wait time of 6 to 18 months (n = 397), respectively (P = 0.049). When only pre-LT factors were considered, wait time of less than 6 or greater than 18 months (HR, 1.6; P = 0.043) and AFP greater than 400 at HCC diagnosis (HR, 3.0; P < 0.001) predicted HCC recurrence in multivariable analysis. Conclusions. This large multicenter study provides evidence of an association between very short (<6 months) or very long (>18 months) wait times and an increased risk for HCC recurrence post-LT. The so-called sweet spot of 6 to 18 months should be the target to minimize HCC recurrence.
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Background. It has been postulated that short wait time before liver transplant (LT) for hepatocellular carcinoma (HCC) results in the inclusion of tumors with aggressive biology, but prolonged wait time could result in a shift to more aggressive tumor behavior. We therefore test the hypothesis that a wait time "sweet spot" exists with a lower risk for HCC recurrence compared with the other 2 extremes. Methods. This multicenter study included 911 patients from 3 LT centers with short, medium, and long wait times (median of 4, 7, and 13 months, respectively) who received Model for End Stage Liver Disease exception listing for HCC from 2002 to 2012. Results. Wait time, defined as time from initial HCC diagnosis to LT, was less than 6 months in 32.4%, 6 to 18 months in 53.7%, and greater than 18 months in 13.9%. Waitlist dropout was observed in 18.4% at a median of 11.3 months. Probability of HCC recurrence at 1 and 5 years were 6.4% and 15.5% with wait time of less than 6 or greater than 18 months (n = 343) versus 4.5% and 9.8% with wait time of 6 to 18 months (n = 397), respectively (P = 0.049). When only pre-LT factors were considered, wait time of less than 6 or greater than 18 months (HR, 1.6; P = 0.043) and AFP greater than 400 at HCC diagnosis (HR, 3.0; P < 0.001) predicted HCC recurrence in multivariable analysis. Conclusions. This large multicenter study provides evidence of an association between very short (<6 months) or very long (>18 months) wait times and an increased risk for HCC recurrence post-LT. The so-called sweet spot of 6 to 18 months should be the target to minimize HCC recurrence. 1 were adopted by United Network for Organ Sharing (UNOS) in granting priority listing status for liver transplant (LT) for patients with hepatocellular carcinoma (HCC) under the Model of End-stage Liver Disease (MELD) organ allocation system, the demand for liver allografts for the treatment of HCC has been steadily rising. Hepatocellular carcinoma now accounts for greater than 20% of all LT in the United States, compared with less than 5% before 2002. 2 Consensus guidelines stipulate that LT for HCC should be reserved for those with a predicted 5-year survival comparable to non-HCC patients. 3, 4 Despite adherence to the Milan criteria, post-LT survival for HCC remains slightly worse than for non-HCC indications, 5 and HCC recurrence still occurs in 10% to 20% of patients after LT. [6] [7] [8] In addition to tumor burden based on tumor numbers and diameter, 9 other well-established tumor characteristics associated with poor post-LT outcomes include presence of microvascular invasion 6, 9, 10 and elevated alpha-fetoprotein (AFP). [11] [12] [13] However, tumor stage (within or beyond Milan) is underestimated by preoperative imaging in 20% to 30%, 6, 10 and the presence of microvascular invasion cannot be ascertained before LT.
14 Consequently, there is a need to identify other potentially modifiable pre-LT factors that impact HCC recurrence after LT. 15 It has been postulated that short wait time or rapid LT results in the inclusion of tumors with aggressive biological behavior and high risk for post-LT recurrence. 16, 17 Several studies using the UNOS database for HCC patients undergoing LT have demonstrated an association between shorter wait time and worse survival 18, 19 and a higher rate of HCC recurrence. 20 Prolonged wait time is associated with a dropout rate of 20% at 1 year from LT listing 21 and may shift tumor biology to become more aggressive over time, leading to increased HCC recurrence after LT. The effects of wait time on post-LT outcomes are especially important in the context of projected increased wait times in the United States for HCC patients because of 2 recent UNOS policy changes: a mandatory 6-month wait time before granting MELD exception and an HCC MELD exception cap at 34 points. 22, 23 Given the concerns related to very short and long wait times, we hypothesize that a wait time "sweet spot" exists which begins after a minimum period of observation to exclude those with very aggressive tumor biology from LT. To test this hypothesis within the framework of existing regional inequalities, we evaluated the impact of wait time on post-LT HCC recurrence in patients with HCC receiving MELD exception at 3 LT centers with short, medium, and long wait times.
MATERIALS AND METHODS

Study Design
This is a multicenter cohort study of patients aged 18 years or older with HCC within Milan criteria based on imaging listed for LT with MELD exception from 2002 to 2012. The 3 centers chosen represented centers with long (UCSFcenter 1), medium (Mayo Clinic Rochester-center 2), and short (Mayo Clinic Jacksonville-center 3) wait times, defined in this study as time from HCC diagnosis to LT. Hepatocellular carcinoma diagnosis was determined to be a more appropriate start date since date of listing with MELD exception depends on when a patient with known HCC is referred to an LT center and other factors, and the patient may have already had local-regional treatments (LRTs). Among the 1151 patients listed with MELD exception at the 3 centers, 240 patients were excluded: 214 with HCC beyond Milan criteria at diagnosis requiring down-staging, 8 lost to follow-up within 1 month of listing, and 18 with cholangiocarcinoma found on explant.
Decisions regarding management of patients with HCC awaiting LT were made at each center's multidisciplinary tumor board, and all patients underwent contrast-enhanced computed tomography or magnetic resonance at a minimum of every 3 months. The general practice at all 3 centers was to use transarterial chemoembolization as first-line LRT with intent for continued treatment to achieve complete tumor necrosis before LT. Explant pathology was reviewed to determine histological grade based on the modified Edmondson criteria, 24 tumor stage based on viable tumors, and presence of vascular invasion.
Outcomes
The primary outcome studied was post-LT HCC recurrence, which was obtained from each individual center's LT database. Additional outcomes studied included post-LT survival and dropout from the transplant waiting list for any of the following reasons: death without LT, HCC tumor progression beyond Milan criteria, being too sick or medically unsuitable to undergo LT, noncompliance, patient decision not to undergo LT, or being lost to follow-up.
Statistical Analysis
Patient characteristics were summarized using medians and interquartile ranges (IQRs) for continuous variables and proportions for categorical variables. The cumulative incidence of dropout was estimated using competing risks (CRs). 25 Post-LT survival and HCC recurrence were evaluated using the Kaplan-Meier method, both overall and stratified by multiple time cutoffs from HCC diagnosis to LT. Univariate and multivariable hazard ratios (HRs) for predictors of post-LT HCC recurrence were determined using Cox proportional hazards regression. This was performed both for all variables and separately for only variables known before transplant (eg, exclusion of explant data and AFP at transplant). Multiple cutoffs for wait time were evaluated using Akaike information criterion (AIC) with lower AIC values indicating better model fit. Predictors of HCC recurrence with a univariate P < 0.1 were evaluated in the multivariate analysis with the final model selected by backward elimination (P for removal, >0.05). Center was added to the final multivariate model to account for center variability. LOESS curve fitting (local polynomial regression) was used to evaluate the optimal wait time. Statistical analyses were performed using SAS v9.4 and Stata/IC 11.1.
RESULTS
Patient Characteristics
Baseline demographic and clinical characteristics of the 911 patients comprising the study population are summarized in Table 1 . The median age was 58 (IQR, 53-63), and 74.2% were men. White (59.2%), Asian (19.7%), and Hispanic (12.6%) race/ethnicity made up most of the study population with a higher percentage of nonwhite in center 1 than the other 2 centers (P < 0.001). Liver disease due to nonviral hepatitis was more common at centers 2 (39.9%) and 3 (36.5%) than center 1 (13.9%) (P < 0.001). At the time of HCC diagnosis, median MELD score was 11 (IQR, (8) (9) (10) (11) (12) (13) (14) , and median AFP was 13.0 ng/mL (IQR, 5.3-69.0). More than half (52.1%) received a single LRT, 18.4% had 3 treatments or greater, and 6.5% received no LRT. Only 9.5% underwent greater than 1 LRT at center 3 (shortest wait time) compared with 47.6% at center 1 (longest wait time) and 65.0% at center 2 (P < 0.001).
Dropout While on the Waiting List
Ninety-six patients (10.5%) experienced dropout due to tumor progression, and an additional 38 patients (4.2%) died while on the waiting list. Median time from HCC diagnosis to dropout due to tumor progression or death was 11.3 months (IQR, 6.8-16.5). Median time to dropout was 11.6 months at center 1 versus 10.7 and 6.6 months at centers 2 and 3, respectively (P = 0.004). Cumulative probabilities of dropout due to tumor progression or death by CR analysis overall were 3.2% within 6 months, 8.7% within 12 months, and 12.4% within 18 months of HCC diagnosis. When dropout was stratified by center, CR probability of dropout within 18 months was 19.5% at center 1, 4.5% at center 2, and 3.5% at center 3 (P value for center 2 or 3 vs 1 < 0.001) ( Table 2) . Overall, 85.1% of those with waitlist dropout were from center 1. Thirty-four patients were censored at the time of waitlist removal for reasons including Outcomes on the LT waitlist (n = 911) Of the 911 patients in the cohort, 740 (81.2%) underwent LT after a median of 8.4 months (IQR, 4.6-14.1) from HCC diagnosis. Median wait time from HCC diagnosis to LT was 12.9 months at center 1, 7.3 months at center 2, and 4.5 months at center 3 (P < 0.001). The median HCC MELD-exception was 31 at center 1, 28 at center 2, and 25 at center 3. Only 70.5% of patients underwent LT at center 1 compared with 93.4% at center 2 and 94.4% at center 3 (P < 0.001). Only 6 (0.8%) of the 740 patients received live donor LT, all at center 1. The median time from HCC diagnosis to LT was less than 3 months in 13.2%, 3 to 6 months in 19.2%, 6 to 12 months in 35.3%, 12 to 18 months in 18.4%, and greater than 18 months in 13.9%. When stratified by center, 61.4% of patients in center 3 had a wait time of less than 6 months versus 10.3% in center 1, whereas 27.5% of patients in center 1 had a wait time of greater than 18 months compared with 1.8% at both centers 2 and 3 (P < 0.001) ( Table 2) .
For the 740 LT recipients, the median donor age was 45 years (IQR, 31-56). Cold ischemia time was 7.0 hours (5.9-8.6), and warm ischemia time was 35 minutes (29-42).
Explant Tumor Characteristics
Explant tumor characteristics are summarized in Table 3 . Median AFP at LT was 8.1 ng/mL (IQR, 4.0-28.7), and 12.3% had an AFP greater than 100. In the explant, complete necrosis with no residual viable tumor because of LRT was seen in 24.2%. Viable tumors were within Milan criteria in 56.0% and understaged to beyond Milan criteria in 19.8%. No viable tumor in explant was more common at center 1 (39%) than centers 2 (21.6%) and 3 (2.7%) (P < 0.001). The overall incidence of microvascular invasion was 10.8% but was significantly higher in center 3 (16.4%) (P = 0.005). Among patients with viable tumors in the explant, most had either well-differentiated (40.3%) or moderately differentiated HCC (45.5%). Of the 14.1% with poorly differentiated tumor grade, 50.6% were from center 2 (P < 0.001). (Figure 1) . Specifically, 1-and 5-year post-LT survival was 92.9% and 75.9% for wait time of less than 6 months, 92.6% and 78.3% for wait time of 6 to 18 months, and 93.0% and 79.2% for wait time of greater than 18 months (P = 0.56).
Post-LT HCC Recurrence
Hepatocellular carcinoma recurrence occurred in 11.2% at a median of 13.0 months (IQR, 6.0-26.7) from LT. Time to recurrence at center 1 was 17.9 months (8.5-26.9) as compared with 11.7 months (4.9-35.6) at center 2 and 10.4 months (4.4-24.2) at center 3 (P = 0.44). The most common sites of initial recurrence were lung (44%), bone (30%), liver (26%), and peritoneum (26%). Overall post-LT recurrence within 1 and 5 years was 5.4% and 12.5%, respectively, and 72.3% of all recurrences occurred within 2 years of LT. There were no significant differences in rates of recurrence seen when stratified by center. Specifically, recurrence rates within 5 years of LT were 13.2% at center 1, 9.5% at center 2, and 14.3% at center 3 (P = 0.45). However, when stratified by wait time to LT, there was a trend toward increased probability of recurrence within 5 years with either wait time of less than 6 months (14.5%) or greater than 18 months (19.0%) as compared with a wait time of 6 to 18 months (9.8%) (P = 0.09). When the short (<6 month) and long (>18 months) wait time groups were combined (n = 343), the 1-and 5-year cumulative probabilities of HCC recurrence were 6.4% and 15.5%, which was significantly higher than that of the group with wait time of 6 to 18 months (4.5% and 9.8%, respectively; P = 0.049) (Figure 2 ). Liver transplant recipients with wait time of less than 6 or greater than 18 months comprised 46.3% of the overall cohort but accounted for 56.6% of the HCC recurrences.
Predictors of Post-LT HCC Recurrence
The results of univariate analysis of wait time as a predictor of HCC recurrence are summarized in Table 4 . There was an insignificant trend toward increased recurrence seen with wait time of less than 6 months (HR, 1.44; 95% CI, 0.90-2.31; P = 0.13) and greater than 18 months (HR, 1.84; 95% CI, 0.99-3.41; P = 0.055). When these 2 wait time groups were combined, wait time of less than 6 or greater than 18 months nearly reached statistical significance as a predictor of HCC recurrence (HR, 1.54; 95% CI, 0.995-2.37; P = 0.052). This combined wait time of less than 6 or greater than 18 months had the lowest AIC among the cutoffs tested (Table 4 ). There was no association seen with shorter wait times of less than 3, less than 4, or less than 5 months and increased recurrence risk.
The results of additional univariate and multivariable analysis of predictors of post-LT HCC recurrence are summarized in Table 5 . Predictors of HCC recurrence in univariate analysis included microvascular invasion, explant tumor > Milan, and moderately and poorly differentiated tumor grade. Additionally, AFP at HCC diagnosis and at LT as a continuous variable and at all tested cutoffs including greater than 100, greater than 400, and greater than 1000 was a significant predictor of HCC recurrence. Age, sex, MELD score, race/ethnicity, etiology of liver disease, number of lesions at HCC diagnosis, number of LRTs received, donor age, and cold and warm ischemia time were not predictive of recurrence on univariate analysis nor was there any center effect seen.
Predictors of HCC recurrence in multivariable analysis included microvascular invasion (HR, 3.58; 95% CI, 2.06-6.21; P < 0.001), explant tumor > Milan criteria (HR, 2.49; 95% CI, 1.10-5.63; P = 0.03), and AFP greater than 100 at transplant (HR, 2.79; 95% CI, 1.72-4.55; P < 0.001). No wait time categories predicted HCC recurrence in this multivariable analysis. However, when only factors known before LT were included (Table 6 ), wait time of less than 6 or greater than 18 months (HR, 1.60; 95% CI, 1.01-2.51; P = 0.043) and AFP greater than 400 at HCC diagnosis (HR, 3.04; 95% CI, 1.68-5.50; P < 0.001) were the only factors predicting HCC recurrence after adjusting for center, tumor number, and etiology of liver disease. Additionally, although wait time of less than 6 or greater than 18 months was not associated with the presence of microvascular invasion or explant stage beyond Milan criteria on logistic regression, it was associated with AFP greater than 100 at LT (HR, 1.63; 95% CI, 1.04-2.56; P = 0.03) as compared with those with wait time of 6 to 18 months.
LOESS curve fitting ( Figure 3) showed recurrence risks increasing for the first 4 to 5 months after HCC diagnosis, then decreasing from 6 to 12 months with the lowest risk around 13 months. The risk then increased slightly to approximately 18 months, suggesting that recurrence risk may be lowest in the 6-to 18-month period.
DISCUSSION
In 2010, the proportion of patients with HCC undergoing LT within 3 months of listing with MELD exception ranged from less than 20% in regions with long wait times to greater than 90% in regions with short wait times. 26 There are perceived risks of transplanting patients with HCC too quickly FIGURE 2. Cumulative probability of HCC recurrence for LT recipients with wait time from HCC diagnosis to LT of less than 6 or greater than 18 months compared with those with wait time "sweet spot" of 6 to 18 months. without a minimal period of observation for tumor progression, as illustrated in the "fast-tracking" and "ablate and wait" concepts, 16, 17 leading to the inclusion of aggressive tumors for LT with a high risk for post-LT recurrence. Several studies using the UNOS database have demonstrated that short wait time is associated with inferior post-LT outcomes. Halazun et al 18 showed that 5-year post-LT survival was significantly worse for patients in short wait time regions (66%) compared with those transplanted in long wait time regions (70%). Similarly, Schlansky et al 19 demonstrated that wait time from listing to LT of less than 3 months was associated with worse overall post-LT survival. It may be argued that there are factors beyond HCC recurrence accounting for the worse post-LT survival seen in those with short wait times, but a third study by Samoylova et al 20 found that a wait time of greater than 4 months was associated with a 40% decrease in HCC recurrence. Nevertheless, the difference in HCC recurrence rates between patients waiting greater than 4 months versus those waiting 4 months or less did not persist at 2 years after LT. These studies are limited by a lack of explant histopathological data, a likely underestimation of HCC recurrence rate in the only study that assessed HCC recurrence, 20 and use of the date of HCC listing rather than HCC diagnosis as the starting point in estimating wait time for LT.
In this large multicenter study, we aimed to assess the impact of wait time from HCC diagnosis to LT on HCC recurrence in centers with short, medium, and long wait times. Not surprisingly, we found microvascular invasion, elevated AFP, and explant stage beyond Milan criteria to be significant predictors of HCC recurrence on multivariable analysis. However, microvascular invasion and explant tumor stage are unknown before LT. When we focused only on factors known before the time of LT, wait time of less than 6 or greater than 18 months and AFP at HCC diagnosis were the only significant predictors of HCC recurrence on multivariable analysis. Patients with wait time of less than 6 or greater than18 months, which comprised nearly half of the cohort, had a nearly 60% increased risk of HCC recurrence within 5 years of LT compared with those with wait time of 6 to 18 months (16% vs 10%). The importance of performing LT within this "sweet spot" was further strengthened by the finding that short or long wait time was significantly associated with increased AFP at LT. Each center had a sizable percentage of patients within the "sweet spot" (62% of center 1, 58% of center 2, and 37% of center 3), and we observed no significant center effects in the analysis of HCC recurrence. Furthermore, LOESS curve fitting suggested that performing LT in this "sweet spot" may be associated with the lowest recurrence risk, although this needs confirmation. The observation of inferior posttransplant outcomes when the wait time is prolonged (>18 months) has not been previously reported. The natural course of HCC after LRT provides some support of the hypothesis of a shift in tumor biological behavior over time. Local-regional treatment is recommended as a bridge to LT for HCC when the expected wait time is at least 6 months, 3 and transarterial chemoembolization is the most commonly used treatment modality. More than 93% in the present study received at least 1 LRT before LT. In a study by Terzi et al, 27 involving 148 patients with a single nodule treated only with transarterial chemoembolization (92% within Milan criteria), relapse after initial complete response occurred in almost two thirds of patients after a median of 9 months, and nearly two thirds had distant intrahepatic relapse rather than just local recurrences at the previous treatment site. Distant intrahepatic tumor recurrence after initial LRT may represent one of many facets of a change in tumor aggressiveness.
Our findings may have important implications under the current climate of organ allocation for HCC. Given the growing body of evidence that patients with HCC are given an unfair advantage in organ allocation over non-HCC patients listed for LT, 26, 28, 29 UNOS implemented policy changes in October 2015 in the attempt to improve disparity in access to LT. They include a mandatory wait time of 6 months from listing before granting MELD exception and a cap of HCC MELD exception at 34 points. 22, 23 Our results suggest that this mandatory delay in time to LT, if staying within a window of 6 to 18 months from the time of HCC diagnosis, should not compromise post-LT outcome and may even further improve LT benefits for HCC. On the other hand, in regions where the wait time is already prolonged for 12 to 18 months for HCC patients receiving MELD-exception, 21 time to LT may be further delayed under the cap 34 policy, potentially leading to worse outcomes after LT. Nevertheless, our results should not imply exclusion from LT those who achieved good disease control but waited longer than 18 months.
One of the main goals of these UNOS policy changes is to narrow the gap in the waitlist removal rates between HCC and non-HCC patients. For patients with HCC, our study clearly demonstrated an imbalance in the rates of waitlist dropout by regions with different wait times. We found low rates of waitlist dropout of 3% to 5% that were nearly identical between centers 2 and 3 with median wait times of 7.3 and 4.4, respectively. It has been shown that the rate of waitlist dropout for HCC patients is not linear but tends to be low in the first 6 months on the waitlist, then increases exponentially over time. 30 In this study, center 1 with the longest wait time (median, 13 months) accounted for 85% of all the waitlist dropouts and had a 20% probability of waitlist dropout at 18 months of HCC diagnosis. Certainly, efforts to reduce regional disparities such as with redistricting may help alleviate the unequal distribution of waitlist dropout currently found in regions with prolonged wait times compared with those with much shorter wait times. Another option to reduce regional disparities while balancing LT rates between HCC and non-HCC patients would be to assign a fixed MELD exception slightly below the median MELD at LT based on region and blood type. Finally, identifying new biomarkers for assessment of tumor aggressiveness 31 and predicting post-LT outcome is of critical importance in future research. DCP (des-gamma-carboxyprothrombin) 32 and selected noncoding RNAs (microRNAs and long noncoding RNAs) 33 hold promise and should be further investigated.
To our knowledge, this is the largest US multicenter study to date on LT for HCC. We used HCC recurrence as the primary end point in assessing the impact of wait time rather than relying on overall survival as evident in most UNOSbased studies. In contrast to previous studies using UNOS data, we used the date of HCC diagnosis rather than date of LT listing as the starting point in defining wait time. Our definition takes into consideration the lag time between HCC diagnosis and referral to the LT center and possible factors that might result in a delay in LT listing. We therefore believe that our definition of wait time results in a more accurate assessment of its impact on HCC recurrence and that changes should be considered for starting wait time from the date of HCC diagnosis rather than date of listing, like kidney transplant policy changes implemented in December 2014 by UNOS/OPTN in which wait time included time spent after starting dialysis.
Our study has limitations, most notably the retrospective study design and lack of information provided for response to LRT, which has been suggested to correlate with risk of HCC recurrence after LT. [34] [35] [36] Analysis of response to LRT is difficult to perform in this multicenter cohort because of multiple time points for evaluation in the center with prolonged waiting time and insufficient duration to observe the full effects of LRT in the center with short waiting time. Like the findings from Terzi et al, 37 the number of LRT received was not predictive of HCC recurrence. Although our study included a large cohort of 911 patients (740 received LT), there were only 83 cases of HCC recurrence which might have limited our ability to detect a stronger association between wait time and HCC recurrence. Finally, we have not yet validated the wait time "sweet spot." A single-center study attempted to identify the "optimal" wait time for LT in HCC patients using an intention-to-treat survival analysis, 38 but we are concerned about the statistical bias as wait time itself is part of the observation. For example, a patient must survive 6 months from HCC diagnosis to be in the 6-to 18-month wait time group, and patients dying within 3 months of diagnosis would automatically be included in the group with wait time of less than 3 months. We therefore chose not to perform an intention-to-treat survival analysis per different wait times as a result of this statistical bias.
In summary, this large multicenter study provides evidence of an association between post-LT HCC recurrence and very short (<6 months) or long (>18 months) wait times from HCC diagnosis to LT. Patients in these categories had an overall 60% increased risk of HCC recurrence compared with those with a wait time of 6 tp 18 months and had higher AFP levels at the time of LT. The so-called wait time "sweet spot" of 6 to 18 months should be the target to minimize HCC recurrence after LT.
